Announcements Trials
Browse Landscape

Phase

Phase 2 32Phase 1 14Phase 1/2 11Phase 3 10Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 4Renal Insufficiency 1Primary Myelofibrosis 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Breast Neoplasms 1

Interventions

fludarabine 2Granulocyte Colony-Stimulating Factor 2Cyclophosphamide 2inebilizumab 1Sirolimus 1Positron-Emission Tomography 1Pemetrexed 1Lenalidomide 1Interleukin-6 1Hyperbaric Oxygenation 1Hydroxychloroquine 1Filgrastim 1Dexamethasone 1Bortezomib 1Blood Specimen Collection 113-valent pneumococcal vaccine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Neoplasms, Plasma Cell × Bortezomib × Clear all
NCT01171092 2017-01-11

A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma

University of Kansas Medical Center

Phase EARLY_PHASE1 Completed
21 enrolled
LymphoidPlasma cell

Lymphoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡